Evaluation of plasma natriuretic peptides as markers for left ventricular dysfunction

Muders, Frank; Kromer, Eckhard P.; Griese, Daniel P.; Pfeifer, Michael; Hense, Hans‐Werner; Riegger, Günter A.J.; Elsner, Dietmar

doi:10.1016/s0002-8703(97)70079-6

Cited by 119 publications

(70 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In three of these, the accuracy of BNP for detection of an LVEF <45%, measured by AUC, was 0.71, 0.738 and 0.718 [20, 21, 29]. Only one of these trials showed that the BNP level was not the most accurate natriuretic peptide investigated [29].…”

Section: Discussionmentioning

confidence: 99%

Evaluation of Brain Natriuretic Peptide in the Diagnosis of Heart Failure

et al. 2000

View full text Add to dashboard Cite

A diagnosis of heart failure (HF) can be difficult, especially in patients with mild symptomatology. The purpose of this study was to evaluate the significance of brain natriuretic peptide (BNP) in the diagnosis of HF with systolic or isolated diastolic ventricular dysfunction. One hundred patients and 9 controls were included in the study. Eighty-five patients were diagnosed with HF, based on clinical and echocardiographic findings. BNP levels were accurate for the diagnosis of HF, with an area under the receiver operating characteristic (ROC) curve (AUC) of 0.92. In addition, BNP levels showed an excellent accuracy for the diagnosis of isolated diastolic HF (AUC = 0.89). These data suggest that the measurement of BNP levels may be helpful in the diagnosis of HF and in selecting patients for further evaluation. Furthermore, BNP measurement can play an important role in the diagnosis of isolated diastolic HF.

show abstract

Section: Discussionmentioning

confidence: 99%

Evaluation of Brain Natriuretic Peptide in the Diagnosis of Heart Failure

et al. 2000

View full text Add to dashboard Cite

show abstract

“…Although the use of BNP levels as a marker of cardiac function has been pursued, most often impaired systolic function has been the primary focus given the classical pathological profile of heart failure caused by reduced contractility. [11][12][13] However, impaired diastolic function is an equally important contributory factor, 3) although it often remains obscure due to lack of recognition. In fact, systolic and diastolic impairment coexist in most patients with heart failure.…”

Section: Discussionmentioning

confidence: 99%

“…As compared to its related A-type natriuretic peptide (ANP) and derivatives, recent studies have confirmed the superiority of BNP measurements in the detection of heart failure. [11][12][13] Today, BNP is the most sensitive biochemical marker of cardiac function available. The role of BNP levels in assessment of cardiac function in asymptomatic subjects, however, remains unclear.…”

mentioning

confidence: 99%

Screening for Cardiac Dysfunction in Asymptomatic Patients by Measuring B-type Natriuretic Peptide Levels.

et al. 2000

View full text Add to dashboard Cite

EART failure is one of the world's leading medical problems.1) Impairment of either left ventricular contraction (e.g. systolic) or compliance (e.g. diastolic) leads to the pathologic condition. 2,3)Heart failure is present in approximately 10 % of the elderly, 4) and patients with asymptomatic left SUMMARYEarly diagnosis and treatment of heart failure lead to improved survival; pre-clinical detection would thus be beneficial. A non-invasive biochemical testing method would indeed be ideal to screen for the condition. In the present study, we sought to determine whether circulating levels of B-type natriuretic peptide (BNP) correlate with cardiac function in asymptomatic subjects. 294 consenting asymptomatic subjects were examined. BNP levels in elevated patients (> 18.4 pg / ml) showed significant correlation with echocardiographic parameters of the systolic and diastolic functions (EF r = − 0.51, FS r = − 0.50, E / A r = 0.42, p < 0.01). Moderate correlation with the CTR on chest X-ray was also seen (r = 0.23, p < 0.01). Multiple regression analysis showed numerous echocardiographic and hemodynamic parameters including those of systolic and diastolic function in addition to left ventricular wall thickness, blood pressure and serum creatinine levels to be significantly associated with raised BNP levels. Elevated BNP levels reflect cardiac function (both systolic and diastolic) in the asymptomatic population. Detection of cardiac dysfunction by the non-invasive biochemical test may prove useful in early pre-clinical diagnosis of heart failure. (Jpn Heart J 2000; 41: 205-214)

show abstract

“…[1][2][3][4]16,17 BNP is more predictive than atrial natriuretic peptide for cardiac mortality in patients with chronic CHF and has provided prognostic information independently of other variables previously associated with poor outcome. 17 In the Australia/New Zealand (ANZ) Heart Failure Study, the recently detected cardiac marker NT-proBNP was evaluated for prediction of all-cause mortality and heart failure in 297 patients with established ischemic left ventricular dysfunction (NYHA class II to III; left ventricular ejection fraction Ͻ45%) treated with carvedilol or placebo.…”

Section: Nt-probnp As a Predictor Of Prognosis In Severe Chfmentioning

confidence: 99%

Prognostic Impact of Plasma N-Terminal Pro–Brain Natriuretic Peptide in Severe Chronic Congestive Heart Failure

et al. 2004

View full text Add to dashboard Cite

Background-The utility of N-terminal proBNP (NT-proBNP) to predict the occurrence of death and hospitalization was prospectively evaluated in the COPERNICUS study, which enrolled patients with an ejection fraction Ͻ25% and symptoms of chronic congestive heart failure at rest or on minimal exertion. Methods and Results-Baseline plasma concentrations of NT-proBNP were measured in a subgroup of 814 men and 197 women with symptoms at rest or on minimal exertion who were enrolled in the COPERNICUS study and were randomized to placebo (nϭ506) or carvedilol (nϭ505). Values of NT-proBNP were markedly increased despite the requirement that patients be euvolemic before the start of treatment (meanϮSD, 3235Ϯ4392 pg/mL; median, 1767 pg/mL). By univariate Cox regression analysis, NT-proBNP was found to be a powerful predictor of subsequent all-cause mortality (relative risk [RR], 2.7; 95% CI, 1.7 to 4.3; Pϭ0.0001 for above versus below median) and all-cause mortality or hospitalization for heart failure (RR, 2.4; 95% CI, 1.8 to 3.4; Pϭ0.0001 for above versus below median). The predictive value of NT-proBNP was similar when both placebo and carvedilol patients were analyzed separately. No significant interaction was found between NT-proBNP and treatment group (Pϭ0.93 for above-versus belowmedian NT-proBNP). Conclusions-NT-proBNP was consistently associated with increased risk for all-cause mortality and for all-cause mortality or hospitalization for heart failure in patients with severe congestive heart failure, even in those who were clinically euvolemic. This marker therefore may be a useful tool in risk stratification of patients with severe congestive heart failure.

show abstract

Evaluation of plasma natriuretic peptides as markers for left ventricular dysfunction

Cited by 119 publications

References 25 publications

Evaluation of Brain Natriuretic Peptide in the Diagnosis of Heart Failure

Evaluation of Brain Natriuretic Peptide in the Diagnosis of Heart Failure

Screening for Cardiac Dysfunction in Asymptomatic Patients by Measuring B-type Natriuretic Peptide Levels.

Prognostic Impact of Plasma N-Terminal Pro–Brain Natriuretic Peptide in Severe Chronic Congestive Heart Failure

Contact Info

Product

Resources

About